Benitec Biopharma (BLT) Cash Flow Statement

Click line-items for a historical chart and %

Net income	-49.87M
Income from discontinued operations
Depreciation of property, plant, and equipment	30.58M
Amortization of intangible assets and deferred financing costs
Loss on disposal or impairment of assets	78.76M
Stock compensation and other non-cash charges
Excess tax benefit from share-based compensation
Deferred income tax expense	-15.62M
(Increase) decrease in accounts receivable	11.77M
(Increase) decrease in inventories	-7.98M
(Increase) decrease in other assets	-7.86M
Increase (decrease) in accounts payable	-6.65M
Increase (decrease) in accrued expenses
Increase (decrease) in other liabilities	-2.05M
Discontinued operations
Net cash provided by operating activities	61.25M
Purchases of property, plant, and equipment	-35.64M
Proceeds from sale of assets	-8.08M
Acquisitions, net of cash acquired	0
Discontinued operations
Net cash used in investing activities	-27.56M
Net repayments under revolving credit facility
Repayment of term loan principal	-253.46M
Debt issuance costs	-5.17M
Excess tax benefit from share-based compensation	0
Proceeds from share-based compensation activity
Taxes paid under share-based compensation activity	-398K
Net cash used in financing activities	-32.6M
Effect of exchange rate changes	-2.4M
Net increase (decrease) in cash and cash equivalents	-1.31M
Cash and cash equivalents at beginning of period	27.25M
Cash and cash equivalents at end of period	25.95M

Entities mentioned with BLT

View All Entities